NKGen Biotech, Inc. financial data

Symbol
NKGN, NKGNW on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
3001 Daimler St,, Santa Ana, California
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Graf Acquisition Corp. IV (to 9/29/2023)
Latest financial report
Q1 2024 - May 20, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 11.4 % -23.8%
Debt-to-equity -133 % -356%
Return On Equity 192 % +45.8%
Return On Assets -263 % -857%
Operating Margin -31.6K %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 24.9M shares +140%
Common Stock, Shares, Outstanding 22.4M shares
Entity Public Float 62.8M USD -62.3%
Common Stock, Value, Issued 2K USD
Weighted Average Number of Shares Outstanding, Basic 21.9M shares +64.8%
Weighted Average Number of Shares Outstanding, Diluted 21.9M shares +64.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Cost of Revenue 0 USD -100%
Research and Development Expense 3.24M USD -10.1%
General and Administrative Expense 15.3M USD +49.4%
Costs and Expenses 7.62M USD +12.1%
Operating Income (Loss) -30.6M USD -0.52%
Nonoperating Income (Expense) 5.95M USD -40.7%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -80M USD -116%
Income Tax Expense (Benefit) 7K USD 0%
Net Income (Loss) Attributable to Parent -80M USD -116%
Earnings Per Share, Basic -5 USD/shares -1.42%
Earnings Per Share, Diluted -5 USD/shares -1.42%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 34K USD -83.6%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD -100%
Other Assets, Current 0 USD
Assets, Current 1.61M USD +444%
Deferred Income Tax Assets, Net 15.4K USD
Property, Plant and Equipment, Net 14.1M USD
Operating Lease, Right-of-Use Asset 482K USD
Assets 16.3M USD -90.7%
Accounts Payable, Current 12.8M USD +119262%
Employee-related Liabilities, Current 733K USD
Accrued Liabilities, Current 1.63M USD -43.8%
Liabilities, Current 37.5M USD +962%
Deferred Income Tax Liabilities, Net 33K USD
Operating Lease, Liability, Noncurrent 348K USD
Liabilities 71.4M USD +1034%
Retained Earnings (Accumulated Deficit) -168M USD -3061%
Stockholders' Equity Attributable to Parent -55.1M USD -902%
Liabilities and Equity 16.3M USD -90.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.03M USD +17.9%
Net Cash Provided by (Used in) Financing Activities 4.01M USD -27.9%
Net Cash Provided by (Used in) Investing Activities 35K USD
Common Stock, Shares Authorized 500M shares +25%
Common Stock, Shares, Issued 22.4M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 8K USD -98.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 284K USD -62%
Interest Paid, Excluding Capitalized Interest, Operating Activities 120K USD
Deferred Tax Assets, Valuation Allowance 33.7M USD +41.6%
Deferred Tax Assets, Gross 1.03M USD +98.4%
Operating Lease, Liability 500K USD
Depreciation 300K USD 0%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -5.38M USD +35.3%
Lessee, Operating Lease, Liability, to be Paid 667K USD
Property, Plant and Equipment, Gross 18.2M USD
Operating Lease, Liability, Current 154K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 249K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 242K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.22 pure
Lessee, Operating Lease, Liability, to be Paid, Year Three 249K USD
Deferred Tax Assets, Operating Loss Carryforwards 22.8M USD +27.7%
Preferred Stock, Shares Issued 0 shares
Deferred Federal Income Tax Expense (Benefit) 7K USD 0%
Preferred Stock, Shares Authorized 10M shares +900%
Unrecognized Tax Benefits 551K USD +36.7%
Additional Paid in Capital 123M USD
Preferred Stock, Shares Outstanding 0 shares
Current State and Local Tax Expense (Benefit) 0 USD
Current Federal Tax Expense (Benefit) 0 USD
Depreciation, Depletion and Amortization 295K USD -2.96%
Deferred Tax Assets, Net of Valuation Allowance 34.1M USD +39.2%
Share-based Payment Arrangement, Expense 1.12M USD -11.2%
Deferred State and Local Income Tax Expense (Benefit) 0 USD
Interest Expense 1.07M USD +3044%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%